Laddar...
Recombinant factor VIII Fc for the treatment of haemophilia A
Prophylaxis with factor VIII (FVIII) is the current therapeutic approach for people with haemophilia A. However, standard half‐life (SHL) FVIII products must be injected frequently, imposing a substantial burden on the individual and making it difficult to tailor therapy according to patient need an...
Sparad:
| I publikationen: | Eur J Haematol |
|---|---|
| Huvudupphovsmän: | , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
John Wiley and Sons Inc.
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8252769/ https://ncbi.nlm.nih.gov/pubmed/33650192 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13610 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|